ChemBriefObesity drug developer Corxel to go public in US via SPAC deal
Corxel Pharmaceuticals will go public via a SPAC merger with Amanat Acquisition Corp, raising $377 million to advance its oral obesity and diabetes drug candidate CX11 into late-stage trials. The deal
reuters · 2026-10-26 03:54